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We report a case of a previously healthy man returning to 
the United Kingdom from Lithuania who developed rhomb-
encephalitis and myeloradiculitis due to tick-borne en-
cephalitis. These findings add to sparse data on tick-borne 
encephalitis virus phylogeny and associated neurologic 
syndromes and underscore the importance of vaccinating 
people traveling to endemic regions. 
Tick-borne encephalitis virus (TBEV) is an emerging disease caused by a neurotropic flavivirus; its inci-
dence is increasing in north, central, and eastern Europe 
(1,2). Typical resulting neurologic illnesses include menin-
gitis or meningoencephalitis (3). Cases peak in the summer, 
when contact between humans and tick vectors is highest, 
and infection is associated with time spent in meadows and 
forests (1,2). We report a previously healthy 38-year-old 
man from the United Kingdom who had unusual neurolog-
ic manifestations of TBEV after travel to Lithuania. 
The patient, who had received no travel-related vac-
cinations, traveled to the Kaunas region, where he visited 
woodlands. He reported having received insect bites on his 
feet. Seven days after arriving in Lithuania, he developed 
influenza-like symptoms, which continued after his return 
to the United Kingdom. Ten days later, he reported neck 
stiffness, photophobia, slurred speech, tongue deviation to 
the left, and left leg weakness; the next day, progressive 
bilateral lower limb weakness in his hips, urinary retention, 
and constipation developed. At that time, he sought treat-
ment at a hospital. 
On examination, the patient was febrile (38.0°C) and 
had a peripheral leukocyte count of 15 × 109 cells/L and C-
reactive protein of 120 mg/L. Cauda equina syndrome was 
ruled out by using lumbar-sacral magnetic resonance imag-
ing; results of a computed tomography scan of the head 
were unremarkable. Pleocytosis was identified in the cere-
brospinal fluid (CSF), and the patient was empirically treat-
ed with ceftriaxone and acyclovir (Appendix Table, https://
wwwnc.cdc.gov/EID/article/25/12/19-1017-App.pdf). 
Two days after neurologic signs began, the patient be-
came breathless and drowsy. Neurologic examination re-
vealed dysarthria, interrupted saccades, and difficulty with 
alternating lateral tongue movements. He exhibited a pout 
reflex and a brisk jaw jerk. Upper limbs had normal tone; 
power was graded 4+/5 on the Medical Research Council 
(MRC) scale (https://mrc.ukri.org/research/facilities-and-
resources-for-researchers/mrc-scales/mrc-muscle-scale) 
for shoulder abduction and elbow extension bilaterally but 
was otherwise normal. The patient had reduced tone in his 
lower limbs and bilateral proximal muscle weakness affect-
ing hip and knee flexors (MRC grade 1–2/5); distal limb 
power was less affected (MRC grade 4/5). He was areflexic 
and had bilateral flexor plantars. Pinprick testing indicated 
dermatomal sensory loss isolated from L2 to L5 on the left. 
Forced vital capacity was 800 mL (reference >1,700 mL); 
therefore, due to respiratory muscle weakness, he was intu-
bated and transferred to a neurology hospital. Repeat CSF 
testing showed a profile similar to the initial test (Appendix 
Table). Antituberculosis therapy was added because of the 
enigmatic etiology. 
Magnetic resonance imaging of the brain and spinal 
cord demonstrated long-segment myelitis with high T2 sig-
nal in the central cord extending from C2 through T12; no 
intracranial lesions or pathological enhancement were seen 
(Figure). Neurophysiology test results pointed to a pregan-
glionic lesion, with decreased compound muscle action po-
tentials in the L4–S1 myotomes, in the context of a normal 
motor conduction velocity and sensory nerve action poten-
tial. Mild denervation affecting L4–S1 roots did not explain 
the patient’s degree of weakness. His neurologic syndrome 
was consistent with rhombencephalitis and myeloradiculi-
tis. High-dose steroid was added to cover the possibility of 
neuromyelitis optica. 
Blood and CSF were screened for inflamma-
tory and infective etiologies (Appendix Table). Serum 
and urine samples were sent to the Rare and Imported 
Pathogens Laboratory (Porton Down, UK) for sero-
logic and PCR testing for alphaviruses, flaviviruses, 
and rickettsial infections. Serum and urine PCR re-
sults were positive for TBEV RNA; serum and CSF re-
sults were positive for TBEV IgG (Appendix Table). 
Metagenomic RNA sequencing confirmed TBEV. A to-
tal of 129 reads (0.01% of total reads) were identified 
as TBEV, sufficient to elucidate the full envelope gene 
sequence at a minimum coverage depth of 5× (when 
mapped to reference sequence GenBank accession no. 
KC154190.1). No reads were observed for other patho-
gens. Phylogenetic analysis of the envelope gene revealed 
the isolate was most closely related to the European 
TBEV clade (GenBank accession no. MK992869) (Ap-
pendix Figure). 
Detection of TBEV RNA from both blood and urine is 
diagnostic of acute TBEV infection (1). On day 14, antibi-
otics, antivirals, and steroids were stopped; antituberculo-
sis therapy had been halted earlier. The patient was extu-
bated on day 17 and has slowly recovered. However, he has 
residual profound proximal left leg weakness and bladder 
and bowel dysfunction.
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Figure. Neurologic manifestations of tick-borne encephalitis 
in a 38-year-old man from the United Kingdom after travel to 
Lithuania. A) Magnetic resonance imaging of the brain and spinal 
cord at onset of neurologic signs, showing possible longitudinal 
extensive transverse myelitis in the cervical and thoracic cord, 
with involvement of the central gray matter. B) One month later, 
increased T2 signal and mild swelling of the central gray matter of 
the cervical cord have both regressed, with some residual subtle 
signal changes throughout the spinal cord. Left, axial images; 
right, sagittal images.
Several subtypes of TBEV cause disease: European, 
Siberian, and Far Eastern (1). Siberian and Far Eastern 
have been associated with worse outcomes (1), but the po-
tentially fatal neurologic complications in this patient are 
consistent with emerging data indicating that the European 
subtype causes more severe disease than previously thought 
(4–6). In <10% of cases, TBEV targets the anterior horn of 
the spinal cord, resulting in flaccid poliomyelitis-like pa-
ralysis (3,7), or, rarer still, as in this case, in paralysis of 
respiratory muscles, requiring artificial ventilation (3,8,9).
Treatment of TBEV is supportive only; vaccination 
and avoiding mosquito bites are key to disease prevention 
and control. Although some TBEV-endemic countries have 
vaccination programs, level of uptake varies (10). Public 
health experts recommend that travelers undertaking high-
exposure activities in endemic countries get vaccinated. 
This case underscores the importance of vaccination among 
groups of susceptible people and improved awareness of 
this emerging disease. 
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We report a case of Aspergillus felis infection in a patient 
with chronic granulomatous disease who had overlapping 
features of invasive pulmonary aspergillosis and allergic 
bronchopulmonary aspergillosis. Identifying the species 
responsible for aspergillosis by molecular methods can be 
crucial for directing patient management and selection of 
appropriate antifungal agents.
A 42-year-old man with X-linked chronic granuloma-tous disease (CGD) sought care at a hospital in Paris, 
France, for a 2-week history of cough and night sweats. 
He had been receiving long-term prophylaxis with itra-
conazole (400 mg/d) and had normal trough levels (1,240 
µg/L) 1 month before his hospital visit. 
At admission, blood counts showed mild leukocyto-
sis (leukocytes 9.6 × 109 cells/L, reference range 4–10 × 
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